Your browser doesn't support javascript.
loading
Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
Ludwig, Julia; Scally, Stephen W; Costa, Giulia; Hoffmann, Sandro; Murugan, Rajagopal; Lossin, Jana; Prieto, Katherine; Obraztsova, Anna; Lobeto, Nina; Franke-Fayard, Blandine; Janse, Chris J; Lebas, Celia; Collin, Nicolas; Binter, Spela; Kellam, Paul; Levashina, Elena A; Wardemann, Hedda; Julien, Jean-Philippe.
Afiliação
  • Ludwig J; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Scally SW; Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Costa G; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Hoffmann S; Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
  • Murugan R; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lossin J; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Prieto K; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Obraztsova A; Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Lobeto N; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Franke-Fayard B; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Janse CJ; B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lebas C; Malaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
  • Collin N; Malaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
  • Binter S; Vaccine Formulation Institute, Plan-les-Ouates, Switzerland.
  • Kellam P; Vaccine Formulation Institute, Plan-les-Ouates, Switzerland.
  • Levashina EA; Kymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
  • Wardemann H; Kymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
  • Julien JP; Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
NPJ Vaccines ; 8(1): 52, 2023 Apr 07.
Article em En | MEDLINE | ID: mdl-37029167

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 3_ND Problema de saúde: 1_doencas_transmissiveis / 3_malaria / 3_neglected_diseases Idioma: En Revista: NPJ Vaccines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 3_ND Problema de saúde: 1_doencas_transmissiveis / 3_malaria / 3_neglected_diseases Idioma: En Revista: NPJ Vaccines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
...